FDA Determines Regulatory Review Period for COFLEX INTERLAMINAR TECHNOLOGY Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for COFLEX INTERLAMINAR TECHNOLOGY, a medical device patent, in accordance with federal regulations and in response to a formal application submitted to the U.S. Patent and Trademark Office (USPTO).